Supriya Goud

611 total citations
23 papers, 116 citations indexed

About

Supriya Goud is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Supriya Goud has authored 23 papers receiving a total of 116 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 3 papers in Surgery. Recurrent topics in Supriya Goud's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (7 papers). Supriya Goud is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (7 papers). Supriya Goud collaborates with scholars based in India, Denmark and United Kingdom. Supriya Goud's co-authors include Sucheta More, Kumar Prabhash, Vijay Patil, Vanita Noronha, Amit Janu, Abhishek Mahajan, Alok Goel, Rajiv Kumar, Anant Ramaswamy and Nikhil Pande and has published in prestigious journals such as Journal of Clinical Oncology, Oncotarget and Journal of Thoracic Oncology.

In The Last Decade

Supriya Goud

18 papers receiving 112 citations

Peers

Countries citing papers authored by Supriya Goud

Since Specialization

Citations

This map shows the geographic impact of Supriya Goud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Supriya Goud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Supriya Goud more than expected).

Fields of papers citing papers by Supriya Goud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Supriya Goud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Supriya Goud. The network helps show where Supriya Goud may publish in the future.

Co-authorship network of co-authors of Supriya Goud

This figure shows the co-authorship network connecting the top 25 collaborators of Supriya Goud. A scholar is included among the top collaborators of Supriya Goud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Supriya Goud. Supriya Goud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nutritional status and impact on outcomes of patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: a pre-planned secondary analysis of a phase 3 randomized controlled trial 2025 ·Journal of the Egyptian National Cancer Institute ·(unknown), (unknown), (unknown), Nandini Menon, (unknown), Supriya Goud, Sucheta More, (unknown), Vijayalakshmi Mathrudev, (unknown)	0
2	Carica papaya leaf extract (CPLE) versus placebo to improve chemotherapy induced thrombocytopenia (CIT): Results of a phase III triple blinded, randomized placebo controlled trial (PACT study). 2025 ·Journal of Clinical Oncology ·Vikas Ostwal, (unknown), (unknown), (unknown), Prabhat Bhargava, (unknown), (unknown), (unknown), S. Srinivas, Anuj Gupta, Akhil Kapoor, Omshree Shetty, (unknown), Sucheta More, Supriya Goud, Kumar Prabhash, (unknown), Amit Joshi, Jaya Ghosh, Sudeep Gupta	0
3	An open label randomized non-inferiority trial comparing adjuvant platinum plus paclitaxel to platinum plus 5-FU after curative resection in high-risk penile carcinoma. 2025 ·Journal of Clinical Oncology ·(unknown), Vanita Noronha, Nandini Menon, (unknown), Vijay Patil, Amit Joshi, Gagan Prakash, (unknown), Amandeep Arora, (unknown), Supriya Goud, Sucheta More, Akanksha Yadav, (unknown), Priyamvada Maitre, Santosh Menon, Palak Popat, Nilesh Sable, (unknown), Kumar Prabhash	0
4	Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study 2023 ·Medical Oncology ·Vanita Noronha, Vijay Patil, Nandini Menon, (unknown), (unknown), (unknown), Supriya Goud, (unknown), Kavita Nawale, Srushti Shah, (unknown), Vijayalakshmi Mathrudev, (unknown), (unknown), Ashish Singh, (unknown), (unknown), (unknown), Suman Kumar, Abhishek Mahajan, Kumar Prabhash	2
5	A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer. 2023 ·Journal of Clinical Oncology ·Vanita Noronha, Supriya Goud, (unknown), Sucheta More, Akanksha Yadav, (unknown), Nandini Menon, (unknown), Vijay Patil, (unknown), (unknown), (unknown), Srushti Shah, Kavita Nawale, (unknown), (unknown), Shripad Banavali, (unknown), Rajendra Badwe, Kumar Prabhash	0
6	Audit of screen failure in 15 randomised studies from a low and middle-income country 2022 ·ecancermedicalscience ·(unknown), Vijay Patil, Kavita Nawale, Vanita Noronha, (unknown), (unknown), Sucheta More, Supriya Goud, (unknown), Vijayalakshmi Mathrudev, (unknown), Sachin Dhumal, (unknown), Kumar Prabhash	2
7	Prevalence and outcomes of frailty in older patients with cancer: A prospective study from geriatric oncology clinic. 2022 ·Journal of Clinical Oncology ·Abhijith Rajaram Rao, Anant Ramaswamy, Sharath Kumar, Shreya Gattani, (unknown), (unknown), (unknown), (unknown), Jayita Deodhar, (unknown), Supriya Goud, Sucheta More, (unknown), (unknown), Nandini Menon, Vijay Patil, Vikram Gota, Shripad Banavali, Kumar Prabhash, Vanita Noronha	2
8	Phase III randomized controlled trial comparing chemotherapy to best supportive care in advanced esophageal and gastroesophageal junction cancer. 2022 ·Journal of Clinical Oncology ·Vanita Noronha, Vijay Patil, Nandini Menon, (unknown), (unknown), Amit Janu, Nilendu Purandare, Rajeev Kumar, Supriya Goud, Sucheta More, Srushti Shah, (unknown), Akanksha Yadav, (unknown), (unknown), (unknown), (unknown), (unknown), Shripad Banavali, Kumar Prabhash	1
9	An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings 2021 ·ecancermedicalscience ·Akhil Kapoor, Vanita Noronha, Amit Joshi, Vijay Patil, Nandini Menon, (unknown), Vikas Talreja, Supriya Goud, Sucheta More, (unknown), Srushti Shah, Anuradha Chougule, Abhishek Mahajan, Kumar Prabhash	2
10	Impact of COVID-19 on oncology clinical trials: A “novel“ challenge 2020 ·Cancer Research Statistics and Treatment ·Vijayalakshmi Mathrudev, Supriya Goud, Sucheta More, (unknown)	4
11	Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C). 2019 ·Journal of Clinical Oncology ·Vanita Noronha, Amit Joshi, Vijay Patil, Anuradha Chougule, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Rajiv Kumar, Sucheta More, Supriya Goud, (unknown), (unknown), Srushti Shah, Akanksha Yadav, Amit Dutt, Vaishakhi Trivedi, Vichitra Behel, Shripad Banavali, Kumar Prabhash	20
12	Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer 2019 ·Oncotarget ·Vijay Patil, Amit Joshi, Vanita Noronha, (unknown), Anuradha Chougule, (unknown), Atanu Bhattacharjee, (unknown), Nikhil Pande, Vijai Simha, Supriya Goud, Sucheta More, Rajiv Kumar, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash	1
13	Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study 2018 ·ecancermedicalscience ·Amit Joshi, (unknown), Vanita Noronha, Vijay Patil, Vaishakhi Trivedi, Supriya Goud, Sucheta More, (unknown), Kumar Prabhash	8
14	Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma 2017 ·ESMO Open ·Vijay Patil, Vanita Noronha, Amit Joshi, Anuradha Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, (unknown), Nikhil Pande, (unknown), Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash	56
15	Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation? 2017 ·Lung India ·Kumar Prabhash, (unknown), Vijay Patil, (unknown), Anuradha Chougule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, (unknown), (unknown), (unknown), (unknown), Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare	2
16	P3.02b-094 Rebiopsy Post Progression in EGFR Mutated Lung Cancer 2017 ·Journal of Thoracic Oncology ·(unknown), Vijay Patil, (unknown), Amit Joshi, (unknown), (unknown), Abhishek Mahajan, Amit Janu, Supriya Goud, Sucheta More, (unknown), Anant Ramaswamy, Nikhil Pande, Alok Goel, Vikas Talreja, Kumar Prabhash	3
17	P3.02b-055 Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC 2017 ·Journal of Thoracic Oncology ·Vikas Talreja, Vanita Noronha, Vijay Patil, Amit Joshi, Anuradha Chougule, Abhishek Mahajan, Amit Janu, Supriya Goud, Sucheta More, (unknown), Anant Ramaswamy, Nikhil Pande, (unknown), Alok Goel, Kumar Prabhash	1
18	Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy 2017 ·ecancermedicalscience ·Vanita Noronha, Vijay Patil, Amit Joshi, Anuradha Chougule, Atanu Bhattacharjee, Rajiv Kumar, Sucheta More, Supriya Goud, (unknown), Anant Ramaswamy, Nikhil Pande, (unknown), Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash	2
19	Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation? 2017 ·PubMed ·Amit Joshi, Vanita Noronha, Vijay Patil, Anuradha Chougule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, (unknown), Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash	1
20	Phase III randomized trial comparing intravenous to oral iron in patients with cancer‐related iron deficiency anemia not on erythropoiesis stimulating agents 2017 ·Asia-Pacific Journal of Clinical Oncology ·Vanita Noronha, Amit Joshi, Vijay Patil, Shripad Banavali, Sudeep Gupta, Purvish M. Parikh, (unknown), Sachin Punatar, Sucheta More, Supriya Goud, (unknown), Kumar Prabhash	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact